ArticleBiomedicine & pharmacotherapy = Biomedecine & pharmacotherapie2025
Diet-incorporated saracatinib, a Src tyrosine kinase inhibitor, counteracts diisopropylfluorophosphate (DFP)-induced chronic neurotoxicity in the rat model.
Article in Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Non-receptor tyrosine kinase signaling pathways and therapeutic implications.Signal transduction and targeted therapy · 2026Review
- Current review on inducible nitric oxide synthase and Src tyrosine kinase inhibitors as disease-modifiers in preclinical models of epilepsy.Histology and histopathology · 2026Review
- Dual targeting of iNOS and Src tyrosine kinase as a superior therapeutic strategy against soman-induced long-term neurotoxicity: multimodal biomarker, imaging, and neurobehavioral outcome analyses.Acta neuropathologica communications · 2026Article
- Assessment of Intramuscular Verapamil as Pharmacological Countermeasure in a Rat Model of Organophosphate DFP-induced Status Epilepticus.Neurotoxicity research · 2025Article
- Mitigating organophosphate nerve agent, soman (GD), induced long-term neurotoxicity: Saracatinib, a Src Tyrosine Kinase inhibitor, as a potential countermeasure.Journal of neuroinflammation · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Acute exposure to diisopropylfluorophosphate (DFP), an organophosphate nerve agent, induces status epilepticus (SE) and epileptogenesis despite treatment with countermeasures immediately after exposure. Epileptogenesis is characterized by increased Src family tyrosine kinases (SFK), nitrooxidative stress, reactive gliosis, and neurodegeneration in the early stage, followed by spontaneous seizures at a later stage. We hypothesized that treating with saracatinib (SAR), an SFK inhibitor, would mitigate the early markers of epileptogenesis. Therefore, in this study, we investigated the effects of SAR in the diet (10-20 mg/kg/day, high-dose or 5-10 mg/kg/day, low-dose) fed for four weeks post-DFP. SAR-in-diet significantly mitigated DFP-induced nitrooxidative stress markers (nitrite, GSH/GSSG) and pro-inflammatory cytokines/chemokine (TNF-α, IL-17, IL-6, IL-18, IL-1α, MCP-1) in serum and cerebrospinal fluid. DFP-exposed rats exhibited increased reactive microglia (IBA1 +CD68) and reactive astrocytes (GFAP+C3) in extrahippocampal and thalamic regions. Both SAR dosing regimens significantly reduced reactive astrogliosis across several brain regions in both sexes, while the low-dose SAR-in-diet significantly reduced both microgliosis and reactive microgliosis in the laterodorsal thalamic (LDT) nucleus in males. Sex-specific effects of SAR at high-dose were observed in astrogliosis in females in the dentate gyrus, subiculum, amygdala, and LDT. Both SAR dosing regimens significantly reduced neurodegeneration (FJB-positive neurons) in males in the centromedian thalamic nucleus. Pearson correlation analyses revealed strong associations between key epileptogenic markers and SAR-in-diet treatment. These findings underscore the complex relationship between the early markers of epileptogenesis and the disease-modifying potential of SAR-in-diet. Additionally, the SAR-in-diet treatment approach is translational and reduces handling stress in animals in long-term studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.